• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肌钙蛋白和B型利钠肽能否检测转甲状腺素蛋白淀粉样变性中的心肌病?

Do troponin and B-natriuretic peptide detect cardiomyopathy in transthyretin amyloidosis?

作者信息

Suhr O B, Anan I, Backman C, Karlsson A, Lindqvist P, Mörner S, Waldenström A

机构信息

Department of Public Health and Clinical Medicine, Umeå University Hospital, Umeå, Sweden.

出版信息

J Intern Med. 2008 Mar;263(3):294-301. doi: 10.1111/j.1365-2796.2007.01888.x. Epub 2007 Dec 5.

DOI:10.1111/j.1365-2796.2007.01888.x
PMID:18069997
Abstract

OBJECTIVES

Cardiomyopathy is a well known complication in familial amyloidotic polyneuropathy (FAP). Troponin T and B-natriuretic peptide (BNP) have been shown to be excellent markers for heart complications in AL-amyloidosis. The aim of the study was to investigate troponin T, troponin I and BNP as markers for myocardial damage and failure in FAP.

DESIGN

Retrospective investigation of patients with FAP.

SETTING

Tertiary referral centre.

SUBJECTS

Twenty-nine patients who had been submitted for evaluation of FAP.

INTERVENTIONS

Two-dimensional M-mode and Doppler echocardiography and strain echocardiographic examination. Measurement of Troponin T, troponin I and BNP.

RESULTS

Troponin T was detectable in only three patients who all had abnormal interventricular septal (IVS) thickness. Troponin I was abnormal in six patients (21%), of which only two had an increased IVS thickness. The heart function was generally well preserved in the patients in spite of hypertrophy of the IVS in 14 patients. BNP was elevated in 22 patients (76%), and it correlated significantly with IVS thickness and basal septal strain.

CONCLUSIONS

Transthyretin amyloid seems to be less harmful to myocytes than that of AL amyloid as evaluated by serum troponin T and I as well as by echocardiography. BNP appears to be a sensitive marker for cardiomyopathy in FAP, and could prove valuable for follow-up purposes as has been shown for AL-amyloidosis patients.

摘要

目的

心肌病是家族性淀粉样多神经病(FAP)中一种众所周知的并发症。肌钙蛋白T和B型利钠肽(BNP)已被证明是AL淀粉样变性中心脏并发症的优秀标志物。本研究的目的是调查肌钙蛋白T、肌钙蛋白I和BNP作为FAP中心肌损伤和衰竭的标志物。

设计

对FAP患者进行回顾性研究。

地点

三级转诊中心。

研究对象

29例接受FAP评估的患者。

干预措施

二维M型和多普勒超声心动图以及应变超声心动图检查。测量肌钙蛋白T、肌钙蛋白I和BNP。

结果

仅在3例患者中检测到肌钙蛋白T,这3例患者的室间隔(IVS)厚度均异常。6例患者(21%)的肌钙蛋白I异常,其中只有2例IVS厚度增加。尽管14例患者存在IVS肥厚,但总体心脏功能良好。22例患者(76%)的BNP升高,且与IVS厚度和基底间隔应变显著相关。

结论

通过血清肌钙蛋白T和I以及超声心动图评估,转甲状腺素蛋白淀粉样变似乎比AL淀粉样变更少损害心肌细胞。BNP似乎是FAP中心肌病的敏感标志物,并且如对AL淀粉样变性患者所显示的那样,可能对随访有价值。

相似文献

1
Do troponin and B-natriuretic peptide detect cardiomyopathy in transthyretin amyloidosis?肌钙蛋白和B型利钠肽能否检测转甲状腺素蛋白淀粉样变性中的心肌病?
J Intern Med. 2008 Mar;263(3):294-301. doi: 10.1111/j.1365-2796.2007.01888.x. Epub 2007 Dec 5.
2
Evaluation of myocardial changes in familial amyloid polyneuropathy after liver transplantation.
Intern Med. 2008;47(24):2133-7. doi: 10.2169/internalmedicine.47.1399. Epub 2008 Dec 15.
3
Circulating matrix metalloproteinases and tissue inhibitors of metalloproteinases in cardiac amyloidosis.循环中的基质金属蛋白酶和金属蛋白酶组织抑制剂在心脏淀粉样变性中的作用。
J Am Heart Assoc. 2013 Mar 12;2(2):e005868. doi: 10.1161/JAHA.112.005868.
4
Role of natriuretic peptide to predict cardiac abnormalities in patients with hereditary transthyretin amyloidosis.利钠肽在遗传性转甲状腺素淀粉样变性患者心脏异常预测中的作用。
Amyloid. 2013 Dec;20(4):212-20. doi: 10.3109/13506129.2013.825240. Epub 2013 Aug 21.
5
Echocardiographic and biohumoral characteristics in patients with AL and TTR amyloidosis at diagnosis.AL型和TTR型淀粉样变性患者诊断时的超声心动图和生物体液特征。
Clin Cardiol. 2015 Feb;38(2):69-75. doi: 10.1002/clc.22353. Epub 2015 Feb 2.
6
Usefulness of plasma B-type natriuretic peptide as a prognostic marker of cardiac function in senile systemic amyloidosis and in familial amyloidotic polyneuropathy.血浆 B 型利钠肽作为老年系统性淀粉样变性和家族性淀粉样多发性神经病心功能预后标志物的作用。
Amyloid. 2013 Dec;20(4):251-5. doi: 10.3109/13506129.2013.844122. Epub 2013 Oct 10.
7
Cardiac Biomarker Change at 1 Year After Tafamidis Treatment and Clinical Outcomes in Patients With Transthyretin Amyloid Cardiomyopathy.替米沙坦治疗 1 年后心脏生物标志物的变化与转甲状腺素蛋白淀粉样心肌病患者的临床结局。
J Am Heart Assoc. 2024 May 21;13(10):e034518. doi: 10.1161/JAHA.124.034518. Epub 2024 May 18.
8
Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis - Report from the Transthyretin Amyloidosis Outcome Survey (THAOS).转甲状腺素蛋白淀粉样变性患者的基因型和表型对心脏生物标志物的影响——转甲状腺素蛋白淀粉样变性结局调查(THAOS)报告
PLoS One. 2017 Apr 6;12(4):e0173086. doi: 10.1371/journal.pone.0173086. eCollection 2017.
9
Noninvasive risk stratification of patients with transthyretin amyloidosis.转甲状腺素蛋白淀粉样变性患者的无创风险分层。
JACC Cardiovasc Imaging. 2014 May;7(5):502-10. doi: 10.1016/j.jcmg.2014.03.002. Epub 2014 Apr 9.
10
The Utility of Tc-DPD Scintigraphy in the Diagnosis of Cardiac Amyloidosis: An Australian Experience.锝-二膦酸盐闪烁扫描术在心脏淀粉样变性诊断中的应用:澳大利亚的经验
Heart Lung Circ. 2017 Nov;26(11):1183-1190. doi: 10.1016/j.hlc.2016.12.017. Epub 2017 Feb 16.

引用本文的文献

1
Advances in the treatment of transthyretin amyloidosis.转甲状腺素蛋白淀粉样变性病的治疗进展
eGastroenterology. 2025 Jul 18;3(3):e100198. doi: 10.1136/egastro-2025-100198. eCollection 2025.
2
High-Sensitivity Cardiac Troponin T to Exclude Cardiac Involvement in TTR Variant Carriers and ATTRv Amyloidosis Patients.高敏心肌肌钙蛋白T用于排除转甲状腺素蛋白(TTR)变异携带者和野生型甲状腺转运蛋白淀粉样变(ATTRv)患者的心脏受累情况。
J Clin Med. 2024 Jan 30;13(3):810. doi: 10.3390/jcm13030810.
3
A Systematic Review of Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy.
转甲状腺素蛋白淀粉样变心肌病患者使用他法米地的系统评价
Cureus. 2021 Sep 23;13(9):e18221. doi: 10.7759/cureus.18221. eCollection 2021 Sep.
4
Transthyretin cardiac amyloidosis: A treatable form of heart failure with a preserved ejection fraction.转甲状腺素蛋白心脏淀粉样变:一种可治疗的射血分数保留型心力衰竭。
Trends Cardiovasc Med. 2021 Jan;31(1):59-66. doi: 10.1016/j.tcm.2019.12.003. Epub 2019 Dec 17.
5
New insights into the clinical evaluation of hereditary transthyretin amyloidosis patients: a single center's experience.遗传性转甲状腺素蛋白淀粉样变性患者临床评估的新见解:单中心经验
Degener Neurol Neuromuscul Dis. 2012 Aug 28;2:93-106. doi: 10.2147/DNND.S24652. eCollection 2012.
6
Imaging cardiac innervation in hereditary transthyretin (ATTRm) amyloidosis: A marker for neuropathy or cardiomyopathy in case of heart failure?遗传性转甲状腺素蛋白(ATTRm)淀粉样变中的心脏神经成像:心力衰竭时神经病变或心肌病的标志物?
J Nucl Cardiol. 2020 Oct;27(5):1774-1784. doi: 10.1007/s12350-018-01477-y. Epub 2018 Oct 29.
7
Transthyretin Cardiac Amyloidosis.转甲状腺素蛋白心脏淀粉样变性
Curr Cardiol Rep. 2017 Aug 24;19(10):97. doi: 10.1007/s11886-017-0911-5.
8
Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis - Report from the Transthyretin Amyloidosis Outcome Survey (THAOS).转甲状腺素蛋白淀粉样变性患者的基因型和表型对心脏生物标志物的影响——转甲状腺素蛋白淀粉样变性结局调查(THAOS)报告
PLoS One. 2017 Apr 6;12(4):e0173086. doi: 10.1371/journal.pone.0173086. eCollection 2017.
9
Transthyretin Cardiac Amyloidosis in Black Americans.美国黑人中的转甲状腺素蛋白心脏淀粉样变
Circ Heart Fail. 2016 Jun;9(6):e002558. doi: 10.1161/CIRCHEARTFAILURE.115.002558.
10
Frequency of Cardiovascular Involvement in Familial Amyloidotic Polyneuropathy in Brazilian Patients.巴西患者家族性淀粉样多神经病中心血管受累的频率
Arq Bras Cardiol. 2015 Nov;105(5):503-9. doi: 10.5935/abc.20150112. Epub 2015 Sep 8.